|
|
Post by mnkdmorelong on Jan 5, 2016 11:26:09 GMT -5
I sense that there are many on this Board who are not connected to reality. The shock of SNY's termination has caused many to vent rather than think.
MNKD is now in a more dire situation. No energy should be put to suing SNY for various misdeeds. This leads to nothing.
Some have voiced an opinion that SNY cancelled the contract so they can buy MNKD. Does this make any sense at all?
In six months, the cost to maintain Afrezza will rise dramatically. Who is going to pay for the ongoing safety study. How about EU certification. So on and so forth. Focus on solving these problems is best for the company. Suing companies just waste critical resources.
If anything I think Desisto's hire is a positive. If it were a wind down scenario, he would never have signed on. I look forward to the 4:30 meeting.
Our ace in the hole is Al Mann. He will not want a failed Afrezza to be a black mark on his distinguished career.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 11:30:07 GMT -5
The other scary part is are we held hostage the next 6 months by SNY until termination is complete.
|
|
|
|
Post by dictatorsaurus on Jan 5, 2016 11:31:47 GMT -5
It was a terrible marriage that simply had to end. Sure MNKD took a hit, but what matters more is the future potential which Sanofi was surely holding back.
You can't promote a drug you don't believe in, and Sanofi never believed in Afrezza.
|
|
|
|
Post by sccrbrg on Jan 5, 2016 11:38:54 GMT -5
It was a terrible marriage that simply had to end. Sure MNKD took a hit, but what matters more is the future potential which Sanofi was surely holding back. You can't promote a drug you don't believe in, and Sanofi never believed in Afrezza. Or they believed in it too much and don't want to lose market share. It was a horrible deal from the beginning with too many conflicting interests. Honestly, mnkds only option right now is to go it alone or partner with someone that is completely outside of the diabetic market. Investors will riot if they bring on another big pharma with worse terms that already has skin in the game. This is probably where the new CEO comes in - assuming they knew in advance. They didn't want Hakan trying to right the ship and go it alone, they wanted someone they already knew was capable of it. |
|
|
|
Post by mnkdmorelong on Jan 5, 2016 11:45:26 GMT -5
It was a terrible marriage that simply had to end. Sure MNKD took a hit, but what matters more is the future potential which Sanofi was surely holding back. You can't promote a drug you don't believe in, and Sanofi never believed in Afrezza. Many on this Board had the impression that SNY sandbagged the roll out of Afrezza. I think the truth is that SNY put in a lot of effort early on. But sales were way too slow for their efforts. So they cut back in recent months just waiting for the first day to cancel. Any other insulin company would have suffered the same fate. |
|
|
|
Post by kdaddyfresh2000 on Jan 5, 2016 11:47:47 GMT -5
It was a terrible marriage that simply had to end. Sure MNKD took a hit, but what matters more is the future potential which Sanofi was surely holding back. You can't promote a drug you don't believe in, and Sanofi never believed in Afrezza. Many on this Board had the impression that SNY sandbagged the roll out of Afrezza. I think the truth is that SNY put in a lot of effort early on. But sales were way too slow for their efforts. So they cut back in recent months just waiting for the first day to cancel. Any other insulin company would have suffered the same fate. Effort? No one knows about the drug. Excuse me - 90-95% of docs and patients have never heard of the drug. Their efforts s$& ed. |
|
|
|
Post by dictatorsaurus on Jan 5, 2016 11:51:59 GMT -5
It was a terrible marriage that simply had to end. Sure MNKD took a hit, but what matters more is the future potential which Sanofi was surely holding back. You can't promote a drug you don't believe in, and Sanofi never believed in Afrezza. Many on this Board had the impression that SNY sandbagged the roll out of Afrezza. I think the truth is that SNY put in a lot of effort early on. But sales were way too slow for their efforts. So they cut back in recent months just waiting for the first day to cancel. Any other insulin company would have suffered the same fate. What did Sanofi exactly do to promote Afrezza? The drug is still virtually unknown. Walk into any pharmacy or talk to most diabetics and you will soon discover most do not know the drug exists. The early adopters and investors took on the role to promote the drug through social media while Sanofi sat back and did nothing. A few ads in time magazine is not "a lot of effort early on". Turn on day time TV and it's plastered with ads for other Sanofi drugs...where are the Afrezza ads? what about the efforts to improve the label? what about EU application? Where's the effort to go global? Like I said, this whole deal stank from early on...better days ahead. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2016 11:55:09 GMT -5
I am trying to think out loud. Others please chime in-
Why would MNKD agree to JPM conference?
1) Is it possible they did not know SNY was dropping them
2) Lets spin this as a positive, but I dont see that going well. All questions asked will be negative and how far out they are from BK
3) Will they have something positive to say that day?
|
|
|
|
Post by bradleysbest on Jan 5, 2016 12:07:43 GMT -5
JP Morgan seems like years away... What will Al & Duane say today is the key!
|
|
|
|
Post by mnkdmorelong on Jan 5, 2016 12:10:58 GMT -5
I am trying to think out loud. Others please chime in- Why would MNKD agree to JPM conference? 1) Is it possible they did not know SNY was dropping them 2) Lets spin this as a positive, but I dont see that going well. All questions asked will be negative and how far out they are from BK 3) Will they have something positive to say that day? If MNKD did not know this was coming, their antennas need to be calibrated. BK occurs when bonds cannot be paid due to low cash. In the case of MNKD, I can see Al Mann footing the bond payments until better days happen. We are aligned with Al; the Afressza IP and FDA approval is tied to MNKD stock. We want to keep this intact. I am positive for today's meeting. Many on this Board want pablum; say anything to sooth the injured soul. This is bad. We need a real new direction; that is the reason for Desisto. If I am wrong, then MNKD management is inept. |
|
|
|
Post by silentknight on Jan 5, 2016 12:14:39 GMT -5
I have to think that the fact that today is the notification of the partnership, and today is the first day of the new CEO is not a coincidence. They also made it clear that MNKD had a conference call today at 4:30. Who do you think is going to be on that phone call? The new CEO.
It was clearly planned and Al and the Board have done the best they can do in trying to set the company up the best position possible for the transition. The conference call will give us an idea of how things look.
Assuming they can address liquidity concerns, maybe though a new loan from the Mann Group long term or usage of the Sanofi milestone payments short term, there's no danger of bankruptcy for now.
If they don't have answers, I'll re-assess my position. Sanofi being gone is a positive development in my opinion. What a way for a new CEO to start. Lol.
|
|
|
|
Post by bradleysbest on Jan 5, 2016 12:15:39 GMT -5
Man 1:30 can't get here fast enough!
|
|
|
|
Post by mnholdem on Jan 5, 2016 12:44:47 GMT -5
I am trying to think out loud. Others please chime in- Why would MNKD agree to JPM conference? 1) Is it possible they did not know SNY was dropping them 2) Lets spin this as a positive, but I dont see that going well. All questions asked will be negative and how far out they are from BK 3) Will they have something positive to say that day? MannKind is basically back to where we were after FDA approval and waiting for a partnership announcement. One way to look at this is that, even with the limited exposure via DTC ads & mailings, MannKind only had to pay 35% of the costs and MannKind does have to pay that loan for another decade according to the agreement.
So, DeSisto must present the advantages of investing with MannKind and its Technosphere drug delivery system. It's going to be a tough crowd because of Sanofi walking away.
I'll be surprised if Duane has much to say about Sanofi, particularly if he thinks that Sanofi sees Afrezza as a threat. That may invite some unwanted retaliation from their former partner. However, I think Duane would be safe in saying that Sanofi's marketing strategy for Afrezza was too limited by targeting only early diabetics who were failing OADs.
|
|
